JOANN Inc. (JOAN) PT Lowered to $24 at BofA Securities

Go back to JOANN Inc. (JOAN) PT Lowered to $24 at BofA Securities

UPDATE: Telsey Downgrades JOANN Inc. (JOAN) to Market Perform

September 3, 2021 5:56 AM EDT

(Updated - September 3, 2021 6:24 AM EDT)

Telsey analyst Cristina Fernandez downgraded JOANN Inc. (NASDAQ: JOAN) from Outperform to Market Perform with a price target of $14 (from $18).

The analyst commented, "We are downgrading our rating on JOAN to Market Perform from Outperform due to... More

After-Hours Stock Movers 09/02: (APOP) (MDB) (PD) Higher; (FBRX) (YEXT) (JOAN) Lower (more...)

September 2, 2021 6:05 PM EDT

After-Hours Stock Movers

Forte Biosciences, Inc. (NASDAQ: FBRX) 82.4% LOWER; announced that topline data from its Phase 2 clinical trial of FB-401 for the treatment of atopic dermatitis failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI).

Cellect Biotechnology Ltd. (NASDAQ: APOP) 12.1% HIGHER; announced the first ApoGraftTM transplantation in a Leukemia patient in the Companys... More

JOANN Inc (JOAN) Tops Q2 EPS by 25c, Sales Miss

September 2, 2021 4:02 PM EDT

JOANN Inc (NASDAQ: JOAN) reported Q2 EPS of $0.12, $0.25 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $496.9 million versus the consensus estimate of $533.2 million.

For earnings history and earnings-related data on JOANN Inc (JOAN) click here.

... More